No Relief in Sight for Pain Therapeutics Investors

Shares of Pain Therapeutics have been lopped in half as Big Pharma partner Pfizer has put Pain's Remoxy, its lead drug candidate, under review. Durect has plunged more than 35%, as its extended-release tech is used in the product. 

In this video, health-care analyst David Williamson picks up the pieces for investors and takes a closer look at the abuse-resistant painkiller space while discussing the future of Pain Therapeutics.

Obamacare will undoubtedly have far-reaching effects. The Motley Fool's new free report, "Everything You Need to Know About Obamacare," lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more. 


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2425472, ~/Articles/ArticleHandler.aspx, 11/27/2014 7:37:14 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement